FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3046747157> ?p ?o ?g. }

• W3046747157 endingPage "2541" @default.
• W3046747157 startingPage "2536" @default.
• W3046747157 abstract "Background Cisplatin (CDDP) and vinorelbine as an adjuvant chemotherapy improve the overall survival of patients with completely resected non‐small cell lung cancer (NSCLC). However, the treatment completion rate is low due to severe adverse events (AEs). Pemetrexed (PEM) has been used in advanced NSCLC due to its high safety and efficacy. Additionally, the safety of a short hydration method for CDDP administration has been previously reported. Here, we investigated the feasibility of CDDP plus PEM with a short hydration method as adjuvant chemotherapy. Methods A total of 21 completely resected nonsquamous NSCLC patients with pathological stage IIA to IIIA disease were enrolled into the study. Adjuvant chemotherapy consisted of four cycles of CDDP (75 mg/m 2 ) plus PEM (500 mg/m 2 ) every three weeks with a short hydration method. The primary endpoint was the treatment completion rate, and the secondary endpoints included toxicity, the two‐year relapse‐free survival (RFS) rate, and the outpatient treatment rate. Results A total of 21 patients (median age: 66 years; 12 males) were enrolled in two centers. All cases were adenocarcinoma with PS0 (71.4%) or PS1 (28.6%). A total of 81.0% of the patients received four cycles of therapy as scheduled and the primary endpoint was met. The rate of outpatient chemotherapy completion after the second cycle was 90.5%. The grade 3 or higher toxicities were anorexia ( n = 2) and pulmonary thromboembolism ( n = 1). No grade 3/4 hematological toxicities or creatinine level elevations were observed. The two‐year RFS rate was 57.3%. Conclusions CDDP and PEM with a short hydration is well tolerated in the outpatient setting with limited toxicity. Key points Significant findings of the study CDDP plus PEM adjuvant therapy with a short hydration method is well tolerated in the outpatient setting with limited toxicity. What this study adds CDDP plus PEM with a short hydration method has the potential to be one of the options of adjuvant therapy in the future." @default.
• W3046747157 created "2020-08-07" @default.
• W3046747157 creator A5008560120 @default.
• W3046747157 creator A5009114502 @default.
• W3046747157 creator A5010566372 @default.
• W3046747157 creator A5013826622 @default.
• W3046747157 creator A5041182728 @default.
• W3046747157 creator A5051847895 @default.
• W3046747157 creator A5057289880 @default.
• W3046747157 creator A5075073055 @default.
• W3046747157 creator A5078824020 @default.
• W3046747157 creator A5082268022 @default.
• W3046747157 creator A5086981064 @default.
• W3046747157 creator A5087151333 @default.
• W3046747157 creator A5088416811 @default.
• W3046747157 date "2020-07-30" @default.
• W3046747157 modified "2023-09-26" @default.
• W3046747157 title "Phase<scp>II</scp>study of adjuvant chemotherapy with pemetrexed and cisplatin with a short hydration method for completely resected nonsquamous non‐small cell lung cancer" @default.
• W3046747157 cites W121252267 @default.
• W3046747157 cites W1910732341 @default.
• W3046747157 cites W1967773376 @default.
• W3046747157 cites W2019407271 @default.
• W3046747157 cites W2029714546 @default.
• W3046747157 cites W2047359518 @default.
• W3046747157 cites W2099725888 @default.
• W3046747157 cites W2104504726 @default.
• W3046747157 cites W2115658330 @default.
• W3046747157 cites W2116971923 @default.
• W3046747157 cites W2117994949 @default.
• W3046747157 cites W2118261787 @default.
• W3046747157 cites W2121960517 @default.
• W3046747157 cites W2127342594 @default.
• W3046747157 cites W2130361883 @default.
• W3046747157 cites W2158234609 @default.
• W3046747157 cites W2165395427 @default.
• W3046747157 cites W2897447905 @default.
• W3046747157 cites W2947880503 @default.
• W3046747157 doi "https://doi.org/10.1111/1759-7714.13567" @default.
• W3046747157 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7471012" @default.
• W3046747157 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32729237" @default.
• W3046747157 hasPublicationYear "2020" @default.
• W3046747157 type Work @default.
• W3046747157 sameAs 3046747157 @default.
• W3046747157 citedByCount "4" @default.
• W3046747157 countsByYear W30467471572020 @default.
• W3046747157 countsByYear W30467471572021 @default.
• W3046747157 countsByYear W30467471572022 @default.
• W3046747157 crossrefType "journal-article" @default.
• W3046747157 hasAuthorship W3046747157A5008560120 @default.
• W3046747157 hasAuthorship W3046747157A5009114502 @default.
• W3046747157 hasAuthorship W3046747157A5010566372 @default.
• W3046747157 hasAuthorship W3046747157A5013826622 @default.
• W3046747157 hasAuthorship W3046747157A5041182728 @default.
• W3046747157 hasAuthorship W3046747157A5051847895 @default.
• W3046747157 hasAuthorship W3046747157A5057289880 @default.
• W3046747157 hasAuthorship W3046747157A5075073055 @default.
• W3046747157 hasAuthorship W3046747157A5078824020 @default.
• W3046747157 hasAuthorship W3046747157A5082268022 @default.
• W3046747157 hasAuthorship W3046747157A5086981064 @default.
• W3046747157 hasAuthorship W3046747157A5087151333 @default.
• W3046747157 hasAuthorship W3046747157A5088416811 @default.
• W3046747157 hasBestOaLocation W30467471573 @default.
• W3046747157 hasConcept C126322002 @default.
• W3046747157 hasConcept C141071460 @default.
• W3046747157 hasConcept C143998085 @default.
• W3046747157 hasConcept C203092338 @default.
• W3046747157 hasConcept C2776256026 @default.
• W3046747157 hasConcept C2776694085 @default.
• W3046747157 hasConcept C2777240266 @default.
• W3046747157 hasConcept C2777863537 @default.
• W3046747157 hasConcept C2778239845 @default.
• W3046747157 hasConcept C2780350996 @default.
• W3046747157 hasConcept C2781451048 @default.
• W3046747157 hasConcept C31760486 @default.
• W3046747157 hasConcept C535046627 @default.
• W3046747157 hasConcept C71924100 @default.
• W3046747157 hasConcept C90924648 @default.
• W3046747157 hasConceptScore W3046747157C126322002 @default.
• W3046747157 hasConceptScore W3046747157C141071460 @default.
• W3046747157 hasConceptScore W3046747157C143998085 @default.
• W3046747157 hasConceptScore W3046747157C203092338 @default.
• W3046747157 hasConceptScore W3046747157C2776256026 @default.
• W3046747157 hasConceptScore W3046747157C2776694085 @default.
• W3046747157 hasConceptScore W3046747157C2777240266 @default.
• W3046747157 hasConceptScore W3046747157C2777863537 @default.
• W3046747157 hasConceptScore W3046747157C2778239845 @default.
• W3046747157 hasConceptScore W3046747157C2780350996 @default.
• W3046747157 hasConceptScore W3046747157C2781451048 @default.
• W3046747157 hasConceptScore W3046747157C31760486 @default.
• W3046747157 hasConceptScore W3046747157C535046627 @default.
• W3046747157 hasConceptScore W3046747157C71924100 @default.
• W3046747157 hasConceptScore W3046747157C90924648 @default.
• W3046747157 hasIssue "9" @default.
• W3046747157 hasLocation W30467471571 @default.
• W3046747157 hasLocation W30467471572 @default.
• W3046747157 hasLocation W30467471573 @default.
• W3046747157 hasOpenAccess W3046747157 @default.
• W3046747157 hasPrimaryLocation W30467471571 @default.

• next